886360-58-3 Usage
Uses
Used in Pharmaceutical Synthesis:
[2-(4-CHLOROPHENYL)-4-METHYL-1,3-THIAZOL-5-YL]METHANAMINE is used as an intermediate in the pharmaceutical industry for the synthesis of various pharmaceuticals. Its unique structural features allow it to serve as a building block for the development of new drugs with potential therapeutic applications.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, [2-(4-CHLOROPHENYL)-4-METHYL-1,3-THIAZOL-5-YL]METHANAMINE is used as a compound of interest for exploring its potential pharmacological properties. Researchers are investigating its interactions with biological targets, which may lead to the discovery of new therapeutic agents.
Used in Organic Chemistry:
[2-(4-CHLOROPHENYL)-4-METHYL-1,3-THIAZOL-5-YL]METHANAMINE is also utilized in organic chemistry as a versatile compound for the synthesis of other organic compounds. Its chemical properties make it a valuable contributor to the development of new materials and chemical products.
Check Digit Verification of cas no
The CAS Registry Mumber 886360-58-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,6,3,6 and 0 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 886360-58:
(8*8)+(7*8)+(6*6)+(5*3)+(4*6)+(3*0)+(2*5)+(1*8)=213
213 % 10 = 3
So 886360-58-3 is a valid CAS Registry Number.
886360-58-3Relevant academic research and scientific papers
Zhou, Wenbo,Huang, Anling,Zhang, Yong,Lin, Qingxiang,Guo, Weikai,You, Zihua,Yi, Zhengfang,Liu, Mingyao,Chen, Yihua
, p. 269 - 280 (2015)
Therapeutics of metastatic or triple-negative breast cancer are still challenging in clinical. Herein we demonstrated the design and optimization of a series of hybrid of 2,4-diaminopyrimidine and arylthiazole derivatives for their anti-proliferative properties against two breast cancer cell lines (MCF-7 as human breast cancer and MDA-MB-231 as triple-negative breast cancer). More importantly, some of those compounds with potent antiproliferative activities also indicated excellent inhibitory activities against MDA-MB-231 cell migration. These results suggested that the new series of hybridation of aryl-thiazoles and aminopyrimidines could be identified and developed as novel highly potential anticancer agents against the triple-negative breast cancer as well as metastatic one in the future.
